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INTRODUCTION 
Spinal cord injury (SCI) is characterized by an initial traumatic injury phase, followed 
closely by secondary events that result in edema, ischemia, excitotoxicity, and 
inflammation. The mechanisms of secondary injury are not well defined, but it is clear 
that inflammatory processes play a significant role in functional recovery. While the 
initial traumatic injury is difficult to guard against, the subsequent inflammatory 
cascade represents a therapeutic target for SCI. The only clinical therapy accepted 
currently for acute SCI is methylprednisolone, a therapy that has yielded 
disappointing results, with the data from clinical trails being contradictory and 
inconclusive. 
   The complement system is known to perform a wide range of functions in the 
human body. It forms an essential component of the host immune system and is 
associated with the clearance of molecules of foreign origin as well as the elimination 
of invading pathogens from the body. It plays an important role in adaptive immunity. 
However, it is nonspecific in action and unable to distinguish between self and 
non-self. Under normal conditions, it is strictly regulated by complement regulatory 
molecules. However, in neuroinflammatory disorders, the complement regulatory 
molecules fail to control the activated complement components. These activated 
complement components then act as a double-edged sword and are responsible for the 
degeneration of neurons. The devastating roles of the complement components in 
neurodegenerative disorders are well documented. Spinal cord injury (SCI ), traumatic 
brain injury (TBI),  Alzheimer’s disease (AD), multiple sclerosis (MS), myasthenia 
gravis and Parkinson’s disease (PD) are examples of a few disorders in which 
activated complement components play an important role. Not only do these disorders 
arise out of dysfunction in the normal metabolic machinery, but also 
neuroinflammatory disorders associated with microbial infections show involvement 
of complement components. 
We have shown that complement deficient mice and normal mice treated with a 
complement inhibitor are protected from neuronal injury following SCI, and that they 
have significantly improved functional scores over time compared to control mice. 
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These data indicate an important role for complement in secondary injury, and 
indicate complement inhibition will reduce inflammation and provide neuroprotection 
following spinal cord injury. However, complement-dependent mechanisms involved 
in secondary injury following SCI are not known, and there remain concerns 
regarding the clinical application of the currently available systemic (body-wide) 
complement inhibitors with regard to their safety and efficacy. Complement 
activation products are important for host defense and immune maintenance 
mechanisms, and systemic complement inhibition can compromise the protective and 
beneficial roles of complement. This will not be optimal in patients at risk of infection, 
and urinary tract infection is a frequent complication during initial and ongoing 
medical rehabilitation after SCI. 
     We propose to develop a neuroprotective strategy based on attenuating 
complement-dependent secondary damage after SCI using a novel and validated 
approach. The strategy involves the targeting of complement inhibitors to sites of 
complement activation and injury, and we have shown the approach to be highly 
effective in vitro and in mouse models of SCI and other inflammatory disease 
conditions. The targeting strategy enhanced the activity and protective effect of 
complement inhibitors by 10-20 fold compared to untargeted counterparts. 
Furthermore, untargeted, but not targeted complement inhibitors systemically 
inhibited complement and increased susceptibility to infection in a mouse model. 
    We propose to fully characterize our targeted complement inhibitors in a mouse 
model of SCI. In addition to therapeutic endpoints, we will use different types of 
complement inhibitor to investigate complement-dependent disease mechanisms. We 
will determine relationships between the generation of different complement 
activation products and other molecules associated with inflammation in order to gain 
a better understanding of the mechanisms of secondary tissue injury following SCI. 
These preclinical studies will establish the guidelines necessary for the translation of 
this therapy to the clinic using recombinant human proteins. 
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OBJECTIVES 
 
The objectives of this thesis are as follows: 
1. To investigate the dynamics of complement activation and its role in the 
development of SCI in mice.  
2. To 
To investigate the neuroprotective effect of a novel targeted complement inhibitor 
and 
.  
 
 
METHODS AND MATERIALS 
 
1. Animals 
Female wild-type C57BL/6 and C57Bl/6 C3-deficient C3-/-) mice were obtained 
from Jackson Laboratories (Bar Harbor, ME). Breeding pairs of fB-deficient (fB-/-) 
mice on C57BL/6 background were generated as described and provided by Dr. J. 
Thurman (University of Colorado Health Sciences Center, Denver, CO) and a 
breeding colony established. In mice, there are two genes encoding CD59; CD59a is 
widely expressed and is the primary regulator of the MAC in mice, whereas CD59b 
expression is limited to the testis and, at very low levels, bone marrow. In this study, 
CD59a-deficient mice on C57BL/6 background were used and were generated as 
described. fB and CD59 deficiency was confirmed by genotyping. Mice weighing 
between 18 22 g (6 8 weeks old) were used in experiments. All mice were fed on 
standard laboratory food and given tap water ad libitum with a light dark cycle of 12 
hours.  
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2. Complement Inhibitor-CR2-Crry 
 
The fusion protein CR2-Crry was produced and purified as described previously. In 
brief, a cDNA construct of the recombinant fusion protein was prepared by joining the 
mouse CR2 sequence encoding the four N-terminal short consensus repeat (SCR) 
units (residues 1 257 of mature protein, National Center for Biotechnology 
Information Gen-Bank, accession number M35684) to sequences encoding 
extracellular regions of mouse Crry. The Crry sequence used encoded residues 1 319 
of the mature protein (National Center for Biotechnology Information GenBank, 
accession number NM013499). To join CR2 to Crry, linking sequences encoding 
(GGGGS)2 were used. The recombinant protein was expressed in NSO cells and 
purified by anti-Crry affinity chromatography as described. CR2-Crry has a 
circulatory half-life in C57BL/6 mice of  8 hours. 
 
3. Anti-fB anti-body 
The isolation and characterization of anti-fB mAb 1379 used in these studies was 
described previously, and the mAb effectively inhibits the mouse alternative 
pathway[72]. The mAb was generously provided by Drs. V. M. Holers, J. M. 
Thurman (University of Colorado Health Sciences Center, Denver, CO), and G. S. 
Gilkeson (Medical University of South Carolina). 
 
 
4. Spinal cord injury surgery and antibody treatment  
 
Wild-type (wt) mice were randomized into sham (laminectomy, no SCI damage), 
vehicle control (phosphatebuffered saline [PBS]), and CR2-Crry treatment and anti-fB 
mAb treatment groups. Other groups consisted of C3-deficient (C3-/-), fB-deficient 
(fB-/-) and CD59a-deficient (CD59-/-) mice.  For CR2-Crry treatment were 
administered a single dose of 0.25 mg of CR2-Crry by tail vein injection. All other 
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animals received intravenous injections of phosphate buffered saline. For anti-fB 
mAb treatment, wt mice were randomized into four groups, with mice in each group 
receiving an intravenous injection of 100 µl PBS vehicle control or 2 mg anti-fB mAb 
in 100µl PBS at 1 and 12 hours after surgery, 12 and 24 hours after surgery, or 24 and 
36 hours after surgery. The 2mg dose used was based on previous studies 
characterizing the therapeutic effect of this Ab in mouse models of inflammation.  
 
5. Surgery and care           
 Mice subjected to laminectomy at the level of the 12th thoracic vertebra (T12), 
followed by contusion-induced SCI using the NYU weight drop impactor as described 
previously. After injury, the muscles and the subcutaneous tissue were closed in 
layers, the skin was closed with metal wound clips (World precision instruments), and 
mice were given 1 ml of saline per day for 3 days to compensate for loss of blood and 
dehydration. Bladders were expressed before testing, and each mouse was evaluated 
for 4 5 minutes on the day before surgery, immediately after surgery, and then 
manual bladder expression was performed twice daily until full bladder function was 
observed. Sham mice received a dorsal laminectomy without impact injury. There 
was less than 5% surgical mortality, and zero mortality of mice that recovered from 
surgery. Groups of mice were sacrificed at 1, 3, 7 and 21 days after injury, and spinal 
cords were isolated for analysis. The care of mice and surgical procedures were 
approved by the Medical University of South Carolina s committee for animal 
research, in accordance with the National Institutes of Health Guide for Care and Use 
of Laboratory Animals. 
 
6. Locomotor Function Analysis 
             
Open-field observations of locomotor function recovery were independently scored 
by two observers blinded to experimental groups using the Basso, Beattie and 
Bresnahan (BBB) rating scale developed for rats, but later adapted by others for mice 
or  Basso Mouse Scale (BMS) 
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7.  Histopathological Analysis 
Spinal cords were removed at 1, 3, 7 and 21 days postinjury for histological analysis. 
Immediately after sacrifice, mice were perfused transcardially with PBS followed by 
4% paraformaldehyde in PBS. Spinal cords were then removed, placed into 4% 
paraformaldehyde/PBS, and either cryoprotected in 30% sucrose for 48 hours before 
storing at  -80 C or placed in formalin and processed to paraffin for histological 
analysis. For histological assessment, sections of spinal cord were stained with 
hematoxylin and eosin (H&E) or luxol fast blue (LFB) as previously described (Clark 
G: Staining Procedures. Baltimore, MD: Williams and Wilkins, 1981, pp 111 129) 
and Histopathological damage was assessed quantitatively by an independent 
reviewer blinded to the experimental groups. H&E and LFB sections were scored 
from 0 to 3 for the presence and intensity of inflammatory cell infiltration, neuronal 
vacuolation, and hemorrhage (where 0, is no evidence and 3 severe). Scores were then 
expressed as a cumulative score of 0 9. When assessing recovery at 21 days after 
injury, the extent of demyelination, graded between 0 3 (with 0 being no evidence of 
demyelination) was added for a cumulative score of 0 12. To further quantify spinal 
cord injury, morphometric analyses was conducted to determine the degree of tissue 
sparing after injury. Transverse sections of spinal cord were stained with H&E, and 
the cross-sectioned area of spinal cord was measured at 150 μm increments extending 
2mm either side of the injury epicenter using Zeiss Axiovision image analysis 
software (Carl Zeiss, Oberkochen, Germany). Measurements were averaged for 
animals in each group at each time point as previously described. All assessments 
were performed in a blinded fashion. 
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8. Neutrophil and Macrophage Infiltration 
The presence of infiltrating neutrophils and macrophages was assessed using 
immunohistochemistry on frozen spinal cord sections. Standard immunohistochemical 
methods were used as previously described. Neutrophils and macrophages were 
identified by anti-mouse Gr-1 and Mac-3 (BD Biosciences), respectively. Neutrophils 
and macrophages were quantified at the spinal cord injury epicenter, defined as the 
section exhibiting maximal tissue damage. The total number of neutrophils and 
macrophages were quantified using computerized image analysis methods, as 
previously described. Results are expressed as the number of 
neutrophils/macrophages per mm
2
. Specificity of immunostaining was confirmed by 
both the use of isotype control antibody and by the omission of primary antibody. 
 
9. Complement Deposition 
            
Spinal cord cryosections were fixed in cold acetone for 5 minutes and then washed in 
running water followed by PBS. Sections were then incubated for 1 hour at room 
temperature with either anti-mouse C3 fluorescein isothiocyanate (FITC) (Dako, Ely, 
UK), mouse anti-mouse fB mAb 1379 (see above), rabbit anti rat C9 that is cross 
reactive with mouse C9, or rat anti-mouse CD59 mAb 7A6. For C9 and CD59 
visualization, donkey anti-rabbit FITC and donkey anti-rat FITC antibodies were used. 
For fB visualization, we used a mouse on mouse staining kit and protocol from Vector 
laboratories (Burlingame, CA). Sections were then counterstained with DAPI 
(Thermo Scientific, Rockford, IL) for nuclear detail. Sections were then coverslipped 
and analyzed for fluorescence intensity using a Zeiss LSM5 Confocal microscope. 
Fluorescence intensity for each complement component was scored on a scale of 0 3, 
where 0 is no staining, 1, mild, 2, moderate, and 3, intense. All observations were 
made by an observer blinded to group identities.  
 
 
 
 9 
 
10. Statistical Analysis  
 
 All data are presented as Mean±SEM or mean±SD as indicated. Analyses were 
performed using Statview Analysis Software (version 5; SAS Institute Inc., Cary, NC) 
or SPSS 13.0 for Windows. Statistical significance between groups was determined 
by two-way analysis of variance with Bonferroni/ Dunn’s corrected post hoc t-tests. 
For Locomotor functional analysis, repeated measures of analysis of variance was 
used to determine differences between the groups. P 0.05 was considered 
statistically significant. 
 
 
RESULTS 
 
1. Effect of C3 Deficiency and of Complement Inhibition on Locomotor Recovery 
following SCI 
To investigate the role of complement in SCI, we induced contusion injury to the 
spinal cord in wt mice and in mice deficient in C3, a central protein of the 
complement system and common for all pathways of activation. Following injury, 
locomotor recovery was assessed using the modification of the BBB rating scale. All 
animals had a BBB score of 21 pre-injury and a score of 0 immediately after injury, 
with bilateral hindlimb paralysis (Fig. 3). Two days after injury, and every day 
thereafter through the termination of the study at day 21, the C3-deficient mice had a 
significantly improved BBB score compared to the wild-type controls (P < 0.001) 
(Fig. 3). By day 21 after injury, the C3-deficient mice showed a near normal BBB 
score of 19.6 ± 1.2 (P< 0.001), whereas the BBB score for wild-type mice was only 
11.5 ± 2.14 which was significantly lower than that of C3-deficient mice (P< 0.001). 
These data indicate that C3 plays an important role in the posttraumatic events that 
affect functional recovery. Next, we determined whether C3 blockade, using an 
intravenously administered inhibitor previously shown to target to sites of 
complement activation, is a feasible posttraumatic therapeutic approach for improving 
functional recovery. Using the same spinal cord paradigm, a group of mice were 
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treated with a single intravenous injection of 0.25 mg CR2-Crry at 1 hour after SCI. 
As with the C3-deficient mice, the CR2-Crry-treated mice had a significantly 
improved BBB score compared to shamoperated controls at all time points from day 2 
following traumatic injury (P<0.001) (Figure 3). The C3-deficient mice appeared to 
have a better outcome than the CR2-Crry-treated mice, but the difference was not 
significant. 
 
2. Effect of fB and CD59 Deficiency and of alternative complement pathway 
        inhibition on  Locomotor Recovery following SCI 
          
Contusion injury to the spinal cord was induced in mice deficient in fB or CD59, in 
wt untreated mice, and in wt mice subsequently treated with anti-fB mAb or PBS 
(vehicle). Locomotor function was assessed by the BMS scale, and all mice subjected 
to contusion injury exhibited a BMS score of 0 immediately after injury. Over the 
course of 21 days, locomotor function significantly improved in fB-/- mice and wt 
mice treated with anti-fB mAb at 1 and 12 hours after SCI compared to wt and PBS 
treated controls. There were no significant differences in BMS scores between fB-/- 
mice and antifB treated (1/12 hours) mice over the course of the experiment. When 
anti-fB mAb was administered at 12 and 24 hours after SCI, there was a trend toward 
improved locomotor function when compared to controls, but the difference did not 
reach significance. We also administered anti-fB mAb at 24 and 36 hours post-SCI, 
but there was no difference in functional recovery compared to PBS treated mice 
(data not shown). Unless otherwise stated, all data shown below for anti-fB treated 
mice was obtained using a 1 and 12 hour post-SCI treatment schedule. In contrast to 
the improvement seen in fB-/-mice and anti-fB (1/12 hours) treated mice, recovery of 
locomotor function was significantly impaired in CD59-/-mice compared to wt and 
vehicle treated controls. There was no difference in functional recovery between PBS 
(vehicle) treated mice and untreated wt mice after SCI. 
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3.Effect of Complement Deficiency and Complement Inhibition on Tissue Damage 
And Demyelination after SCI 
 
Spinal cord contusion results in a primary hemorrhage, inflammation, and 
loss/damage of neurons. We determined the effect of fB deficiency, fB inhibition 
(1/12 hours), or CD59 deficiency on spinal cord tissue injury by macroscopic 
examination of spinal cords and by assessment of histological changes within the 
spinal cords post injury. At 72 hours after injury, macroscopic examination of 
control spinal cords demonstrated marked indentation at the injury site with 
evidence of hemorrhage. These features were markedly reduced in fB-/- and 
anti-fB mAb treated animals, but appeared exacerbated in spinal cords from 
CD59-/- mice.  
 
4. Effect of C3 Deficiency and of Complement Inhibition on the Extent of Tissue 
Destruction following SCI 
 
To determine whether C3 deficiency or complement inhibition with CR2-Crry 
attenuated overall spinal cord tissue damage, we determined the cross-sectioned area 
of spinal cords at 100 μm increments extending 2 mm either side of the initial injury 
impact site. Measurements were made using spinal cords isolated from C3-deficient 
mice and mice treated with CR2-Crry or vehicle control (PBS). At 24 hours after 
injury, the profile of tissue damage was similar in both C3-deficient and 
CR2-Crrytreated groups. In the control group, there was a clear trend toward 
increased injury compared to the C3-deficient/inhibited groups, but by 24 hours after 
SCI the difference did not reach statistical significance at the injury site or on either 
side of the injury site. Comparable relative profiles were obtained for the three groups 
of animals at 72 hours after SCI. Seven days after injury, however, there was 
significantly more tissue sparing at and around the injury site in C3-deficient mice 
and in mice treated with CR2-Crry compared to vehicle control mice. There was no 
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difference in tissue sparing between C3-deficient and CR2-Crrytreated mice at 7 days 
after SCI.  
 
5. Effect of C3 deficiency and of complement inhibition on the extent of tissue 
demyelination following SCI  
 
We also analyzed the extent of necrosis and demyelination in cords isolated from the 
different groups of animals 7 days and 21 days after SCI. In the vehicle control group, 
H&E staining of cord sections (centered around the injury site) revealed marked areas 
of necrosis with vacuolization of cells at day 7, with necrosis being somewhat less 
evident at day 21. In contrast, the white matter beneath the injury site in cords isolated 
from C3-deficient mice appeared grossly intact at days 7 and 21. Cords from CR2- 
Crry-treated mice also exhibited significant attenuation of injury when compared with 
vehicle controls, although there appeared to be more vacuolization in the cells within 
the white matter compared to the C3-deficient animals. 
 
6. Histopathology of spinal cord sections after SCI 
  
We next analyzed spinal cords microscopically at the injury epicenter using H&E 
stain to assess the extent of inflammatory cell infiltrate, neuronal vacuolation and 
hemorrhage. Sections were prepared from cords isolated at 24 and 72 hours postinjury, 
and the sections were graded for a total cumulative score of 0 9 (see Materials and 
Methods). Injury to spinal cords was evident in all groups at both 24 and 72 hours. 
No significant differences were noted at 24 hours postinjury, but at 72 hours 
there was significantly less damage seen in fB-/- mice and anti-fB mAb - treated mice 
compared to control mice. In contrast, damage was significantly exacerbated in 
CD59-/- mice compared to controls 72 hours after injury.  
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7. Quantitative assessment of histopathological inflammation and injury 
  
Representative images of spinal cord sections postinjury are shown in Fig. 8, with 
quantification of data shown in. Histologically, control and CD59-/- spinal cord 
sections demonstrated evidence of hemorrhage, pronounced inflammation, neuronal 
cell vacuolation, and demyelination, and while these features existed in fB-/-mice and 
anti-fB mAb - treated mice, they were markedly reduced.  
To further quantify the impact of complement deficiency or inhibition on SCI, we 
analyzed tissue destruction by determining the cross-sectional area of spinal cords at 
150µm increments extending 2 mm either side of the initial injury impact site. In 
accord with our subjective histological assessments, there was significantly increased 
tissue sparing in fB-deficient and fB-inhibited mice, and significantly less tissue 
sparing in CD59-/- mice, when compared to control mice.  
 
 
8. Expression of Neutrophils and Macrophage Infiltration after Spinal Cord Injury 
 
After SCI, the infiltration and activation of neutrophils and macrophages is considered 
to play an important role in the propagation of inflammation and tissue damage. 
Neutrophils are typically the first leukocytes to arrive at the injury site, while 
macrophages/microglia appear later but, unlike neutrophils, persist in the spinal cord. 
Complement activation products provide chemotactic and activating signals for 
neutrophils and macrophages, as well as induce the expression of inflammatory 
cytokines/chemokines and adhesion molecules. Using complement deficient and 
inhibited mice, we investigated the influence of the alternative and terminal 
complement pathways in neutrophil and macrophage infiltration after SCI. 
Inflammatory cell influx was evaluated by immunohistochemical analysis using Gr-1, 
a marker antibody for neutrophils, and Mac-3, a marker antibody for microglia/ 
macrophages. Neutrophils and macrophages were quantified at the site of injury in 
mice from all groups at 1 and 3 or 7 days post-SCI.  
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In this study, the total number of neutrophils and macrophages present on each 
section was counted. No distinction was made between white and gray matter, due to 
the extensive damage noted at 24 and 72 hours postinjury in some groups and because 
sections were analyzed using immunohistochemistry, which did not permit 
morphological evaluation. 
 
 
9. Targeting and Biodistribution of Therapeutically Administered CR2-Crry 
 
We recently demonstrated that intravenously administered CR2-Crry targets sites of 
complement activation in a mouse model of complement-dependent intestine 
ischemia and reperfusion injury. The microenvironment of the spinal cord is different, 
and access of macromolecules and inflammatory cells is restricted by the bloodspinal 
cord barrier. On damage, however, the bloodspinal cord barrier becomes temporarily 
more permeable, and this may account for the access of intravenously administered 
CR2-Crry to its targeting ligand (C3) within the spinal cord. To support the concept 
that CR2-Crry functions by targeting specifically to the spinal cord following injury, 
we assessed the tissue distribution of 
125
I-labeled CR2-Crry in normal control mice 
and in mice subjected to SCI. 
125
I-labeled CR2-Crry was injected intravenously 1 hour 
after SCI, as per therapeutic protocol, and biodistribution determined 12 hours later. 
In control mice (no SCI), CR2-Crry was distributed primarily in the blood, with tissue 
localization restricted to the liver and kidney and, to a lesser extent, the heart. The 
location of CR2-Crry within the kidney and liver is likely associated with the 
nonspecific clearance of the protein. Of note, no 
125
I-labeled CR2-Crry was detected 
in the CNS tissues of the spinal cord or brain, indicating that under normal 
physiological conditions CR2-Crry cannot pass the blood-brain/spinal cord barrier. In 
contrast, there was significant localization of 
125
I-labeled CR2-Crry within the spinal 
cord of injured mice. In the spinal cord, levels of CR2-Crry was highest at the site of 
injury but was also detected at sites rostral and caudal to the site of injury. The 
absence of 
125
I-labeled CR2-Crry in brain tissue of injured mice is also supportive of 
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the specific targeting of CR2-Crry. To further investigate the specific targeting of 
CR2-Crry to the injured spinal cord, we performed immunofluorescent staining with 
an anti- CR2 antibody. CR2 is expressed conservatively and found primarily on B 
cells and dendritic cells. Therefore, the presence of CR2 immunoreactivity within the 
spinal cord was deemed to be indicative of localization of recombinant CR2-Crry 
protein, and indeed no immunoreactivity for CR2 antibody could be detected in sham 
controls or SCI control (untreated) animals (not shown). CR2 immunoreactivity was, 
however, seen in CR2-Crrytreated animals when sections of spinal cord were assessed 
12 hours after SCI. Staining was seen primarily within the white matter around the 
injury site and morphologically appeared to stain oligodendrocytes, fiber tracts, and 
vascular structures. This distribution of CR2 corresponds to the distribution of 
deposited C3 in injured spinal cords reported above, and is a further indication of the 
C3 targeting specificity of CR2- Crry. Staining was also noted, to a lesser degree, in 
the dorsal horns of the gray matter with immunolocalization seen in cells with 
neuronal morphology. 
 
10. Deposition of Complement Activation 
 
To correlate post-traumatic inflammation and injury with complement activation,
 we examined spinal cord sections for deposited C3, fB, and C9 (MAC) by  
immunofluorescence microscopy. 
 
11. Time Course of Complement Activation 1, 24 and 72 hours after SCI 
 
The presence of C3, deposition of which marks a site of complement activation by 
any pathway, was assessed in mice that had undergone SCI and in sham laminectomy 
controls. No staining for C3 was observed in sham operated- animals in any 
compartments of the spinal cord. In contrast, C3 deposition was evident following 
SCI in spinal cords harvested at 1 hour, 2 hours, 4 hours, 12 hours, and 24 hours after 
injury. At 1 hour, 2 hours, and 4 hours post-SCI, C3 deposition was centered to the 
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white matter of the injury site and within the ventral horns of the gray matter. At later 
time points of 12 hours and 24 hours, C3 staining was evident in surviving white 
matter, with staining also present throughout the gray matter and extending into the 
ventral and dorsal horns. By day 3 after injury, complement deposition was almost 
undetectable, with no C3 staining evident at the injury site. This result is different 
from that reported for complement deposition in the rat spinal cord following injury, 
in which complement deposition was evident for up to 42 days after injury. An 
additional apparent difference in the mouse model was that, at all time points, spinal 
cord sections 10 mm rostral and caudal to the injury site showed a much reduced C3 
staining pattern compared to sections taken from the injury site. Complement 
deposition was seen up to 20 mm from the injury site in rats, with no apparent 
decrease in immunoreactivity and with increasing distance from the site of injury. 
However, this apparent difference is likely a consequence of animal size and 
differences in size of impact injury required to produce an equivalent condition. 
 
12. Complement deposition at epicenter of injury 24 h post-SCI 
 
Representative immunofluorescence images showing complement deposition, as well 
as CD59 expression, at 24 hours after injury are shown in Fig. 16. There was no 
evidence of C3, fB, or C9 staining in spinal cords from sham operated mice, and 
expression of CD59 was similar in wt control treated and fB-/- mice and absent in 
CD59-/- mice (Fig. 16). 
 
13. Quantitative assessment of complement deposition post-SCI 
 
 In agreement with previous data obtained using mice (for C3 deposition) and rats 
(for fB and C9 deposition), there was pronounced deposition of all three complement 
proteins in the white and gray matter of control mice at 24 hours postinjury. C3 and 
C9 deposition was significantly lower in fB-deficient and fB inhibited mice compared 
to control mice. As expected, fB was undetectable in fB-deficient mice and was 
detected at only very low levels in fB-inhibited mice. Deficiency of CD59 resulted in 
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significantly increased levels of C9 deposition compared to all groups (including 
controls) but did not effect levels of C3 or fB deposition. 
   Similar relative profiles for C3, fB, and C9 deposition were seen at 72 hours 
post-SCI in all groups, although C3 and fB levels were lower than at 24 hours after 
SCI. C9 levels were similar at 24 and 72 hours after SCI. In this study, we detected 
C3 deposition at 72 hours post-SCI, although at low levels. This is in contrast to our 
previous report that C3 was undetectable in mouse spinal cords 72 hours after injury, 
and we attribute this difference to the use of a different detection antibody (see 
Materials and Methods). 
 
 
14. Histological Analysis of Recovery  
 
 Data presented above show that after SCI, fB-deficient mice and fB-inhibited mice 
(when treated at 1 and 12 hours after SCI) have a significantly improved outcome 
compared with controls in terms of inflammation, tissue injury, and functional 
locomotor recovery. To determine the extent of histological recovery, we analyzed 
spinal cords 21 days after the initial impact injury. H&E and LFB staining of cord 
sections from wt and PBS treated controls revealed demylineation in the central core 
of the white matter beneath the impact site and evidence of vacuolation with some 
necrosis with inflammatory cells still present (Fig. 18 A and B.). By comparison, at 21 
days after SCI, there was markedly less demyelination and inflammation and no 
evidence of necrosis in cords from fB deficient mice and mice treated with anti-fB 
mAb at 1 and 12 hours after SCI. There was no apparent difference in the extent of 
demyelination between the fB-deficient and fB-inhibited (1/12 hours) groups. In 
contrast, CD59-/- mice exhibited a serious lack of structural organization, abundant 
inflammatory cell infiltration, scaring, vacuolation, and no obvious myelin structure. 
Also, in agreement with locomotor recovery data, when anti-fB mAb was 
administered 12 and 24 hours after SCI (or 24 and 36 hours, not shown), there was no 
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significant improvement in histological evidence of recovery when compared to wt 
and PBS treated controls. 
 
 
Conclusions 
 
An impact to the spinal cord results in a primary injury, but the impact also triggers a 
series of downstream events that lead to secondary injury of tissue and the progressive 
degeneration of the spinal cord. Therapeutic interventions that minimize secondary 
injury will improve functional recovery after traumatic injury. Inflammation plays a 
key role in secondary injury following spinal cord injury (SCI). Inflammation is a 
rapid immune response that can be initiated by infection or tissue damage. An 
important component of an inflammatory response is the complement system, a 
collection of blood proteins that form part of the immune system and that can be 
activated by injured cells and tissues. Activation of complement amplifies the 
inflammatory response and produces molecules that can be directly toxic or that can 
recruit and activate cells of the immune system to produce toxic molecules. Inhibiting 
the complement system has been shown to be an effective therapy for inflammatory 
disease in various animal models, and some complement inhibitors are in clinical 
trials. 
We have shown that complement deficient mice and normal mice treated with a 
complement inhibitor are protected from neuronal injury following SCI, and that they 
have significantly improved functional scores over time compared to control mice. 
These data indicate an important role for complement in secondary injury, and 
indicate complement inhibition will reduce inflammation and provide neuroprotection 
following spinal cord injury. However, complement-dependent mechanisms involved 
in secondary injury following SCI are not known, and there remain concerns 
regarding the clinical application of the currently available systemic (body-wide) 
complement inhibitors with regard to their safety and efficacy. Complement 
activation products are important for host defense and immune maintenance 
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mechanisms, and systemic complement inhibition can compromise the protective and 
beneficial roles of complement. This will not be optimal in patients at risk of infection, 
and urinary tract infection is a frequent complication during initial and ongoing 
medical rehabilitation after SCI. 
We propose to develop a neuroprotective strategy based on attenuating 
complement-dependent secondary damage after SCI using a novel and validated 
approach. The strategy involves the targeting of complement inhibitors to sites of 
complement activation and injury, and we have shown the approach to be highly 
effective in vitro and in mouse models of SCI and other inflammatory disease 
conditions. The targeting strategy enhanced the activity and protective effect of 
complement inhibitors by 10-20 fold compared to untargeted counterparts. 
Furthermore, untargeted, but not targeted complement inhibitors systemically 
inhibited complement and increased susceptibility to infection in a mouse model. 
We propose to fully characterize our targeted complement inhibitors in a mouse 
model of SCI. In addition to therapeutic endpoints, we will use different types of 
complement inhibitor to investigate complement-dependent disease mechanisms. We 
will determine relationships between the generation of different complement 
activation products and other molecules associated with inflammation in order to gain 
a better understanding of the mechanisms of secondary tissue injury following SCI. 
These preclinical studies will establish the guidelines necessary for the translation of 
this therapy to the clinic using recombinant human proteins. 
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